Innovation Pharmaceuticals Completes End-of-Phase 2 Meeting with FDA; Brilacidin Oral Rinse to Advance Into Phase 3 Clinical Trials for Prevention of Severe Oral Mucositis - Nasdaq

Innovation Pharmaceuticals Completes End-of-Phase 2 Meeting with FDA; Brilacidin Oral Rinse to Advance Into Phase 3 Clinical Trials for Prevention of Severe Oral Mucositis  Nasdaq

BEVERLY, Mass., Dec. 17, 2018-- Innovation Pharmaceuticals, a clinical stage pharmaceutical company, announced today that the Company and the U.S..

from #Head and Neck by Sfakianakis via simeraentaxei on Inoreader https://ift.tt/2EzMn7q